Homology Medicines, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Alloway
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Patriots Park Bedford MA United States of America 01730
- IPO Date
- Mar 28, 2018
- CIK
- 0001661998
- Website
- homologymedicines.com
- Similar Companies
- Business
- Homology Medicines, Inc. (FIXX) is a clinical-stage genetic medicines company focused on developing gene therapies and nuclease-free gene editing treatments for rare diseases using its proprietary human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs). The company, founded in 2015 and headquartered in Bedford, Massachusetts, targets disorders including phenylketonuria (PKU) with lead candidates HMI-103 (pheEDIT trial gene editing) and HMI-102 (gene therapy); mucopolysaccharidosis type II (MPS II or Hunter syndrome) with HMI-203; metachromatic leukodystrophy (MLD) with HMI-202 and optimized HMI-204; and earlier-stage programs such as HMI-104, along with its GTx-mAb platform for antibody production. Homology operates primarily in the United States, delivering genetic medicines in vivo to restore functional genes in patients with unmet needs in metabolic and lysosomal storage disorders. In March 2024, Homology Medicines completed a merger with Q32 Bio Inc., under which it became a wholly-owned subsidiary operating as Q32 Bio (NASDAQ: QTTB) headquartered in Waltham, Massachusetts, accompanied by a $42 million private placement financing from investors including OrbiMed, Atlas Venture, Bristol Myers Squibb, and Sanofi Ventures to support Q32's autoimmune and inflammatory disease pipeline through mid-2026. The transaction included a 1-for-18 reverse stock split of Homology's common stock and issuance of contingent value rights to shareholders. Homology Medicines declared a distribution to common stockholders in March 2024 and received a NASDAQ minimum bid price deficiency notice in January 2024, with efforts to regain compliance.
Homology Medicines Declares Distribution to Common Stockholders
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders
Q32 Bio and Homology Medicines Announce Merger Agreement
Q32 Bio and Homology Medicines Announce Merger Agreement
Homology Medicines Reports Third Quarter 2023 Financial Results
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX
Best Penny Stocks To Buy? 6 To Watch Before Next Week
Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Homology Medicines, Inc. (FIXX) Shareholders of Class Action Last Few Hours to Actively Participate
HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm